Literature DB >> 24464846

A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure.

Alexander Burashnikov1, José M Di Diego, Serge Sicouri, Michael Xavier Doss, Agapios Sachinidis, Hector Barajas-Martínez, Dan Hu, Yoshino Minoura, N Sydney Moise, Bruce G Kornreich, Liguo Chi, Luiz Belardinelli, Charles Antzelevitch.   

Abstract

AIMS: Heart failure (HF) is associated with development of AF and life-threatening ventricular tachycardia and fibrillation (VT/VF). Vulnerability to development of AF and VT/VF at different stages of HF and the underlying pathophysiological mechanisms are poorly defined. The present study was designed to determine the time-course of development of electrical and structural remodelling of the atria and ventricles, and their contribution to induction of AF and VT/VF in a canine model of HF. METHODS AND
RESULTS: Dogs were ventricular tachypaced (VTP) for 2-3 weeks or 5-6 weeks ('early' and 'late' HF, respectively). Electrophysiological studies were performed in isolated atrial and ventricular preparations and correlated with cardiac dimensions and haemodynamic parameters recorded in vivo. Vulnerability to programmed electrical stimulation-induced AF was greater in early vs. late stages of HF (78% vs. 38%). In contrast, VT/VF was inducible in late but not in early stages of HF (38% vs. 0%). The temporal distinction in atrial and ventricular arrhythmia susceptibility was associated with a much more rapid development of electrical and structural remodelling in atria. Vulnerability to AF developed following moderate electro-structural remodelling and waned with further progression to severe remodelling, which averted rapid atrial activation.
CONCLUSIONS: A temporal window of vulnerability for AF appears relatively early during development of VTP-induced HF in dogs, whereas VT/VF vulnerability is observed at more advanced stages of HF. These findings, if confirmed in humans, may have clinical implications with regard to prognosis and approach to therapy of patients with HF.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Atrial fibrillation; Fibrosis; Heart failure; Ventricular Fibrillation

Mesh:

Substances:

Year:  2014        PMID: 24464846     DOI: 10.1002/ejhf.28

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

Review 1.  Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2018-09-09       Impact factor: 1.976

2.  Heart failure duration progressively modulates the arrhythmia substrate through structural and electrical remodeling.

Authors:  Victor P Long; Ingrid M Bonilla; Pedro Vargas-Pinto; Yoshinori Nishijima; Arun Sridhar; Chun Li; Kent Mowrey; Patrick Wright; Murugesan Velayutham; Sanjay Kumar; Nam Y Lee; Jay L Zweier; Peter J Mohler; Sandor Györke; Cynthia A Carnes
Journal:  Life Sci       Date:  2015-01-14       Impact factor: 5.037

3.  Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.

Authors:  Alexander Burashnikov; José M Di Diego; Hector Barajas-Martínez; Dan Hu; Andrew C Zygmunt; Jonathan M Cordeiro; N Sydney Moise; Bruce G Kornreich; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Heart Fail       Date:  2014-05-29       Impact factor: 8.790

Review 4.  Ca2+ leak-What is it? Why should we care? Can it be managed?

Authors:  Penelope A Boyden; Godfrey L Smith
Journal:  Heart Rhythm       Date:  2017-11-20       Impact factor: 6.343

Review 5.  Heart failure and Alzheimer's disease.

Authors:  P Cermakova; M Eriksdotter; L H Lund; B Winblad; P Religa; D Religa
Journal:  J Intern Med       Date:  2014-08-01       Impact factor: 8.989

6.  Transcriptional changes associated with advancing stages of heart failure underlie atrial and ventricular arrhythmogenesis.

Authors:  Mariana A Argenziano; Michael Xavier Doss; Megan Tabler; Agapios Sachinidis; Charles Antzelevitch
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

Review 7.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

Review 8.  Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

Authors:  Alexander Burashnikov
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.